<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310009</url>
  </required_header>
  <id_info>
    <org_study_id>ANEX</org_study_id>
    <nct_id>NCT02310009</nct_id>
  </id_info>
  <brief_title>IL-1RA, Acute Exercise, and Beta-cell Function</brief_title>
  <acronym>ANEX</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects (N=48) with poorly-controlled type 2 diabetes (HbA1c&gt;7%) will be assigned to one of
      the 4 following interventions in a randomised, parallel group design: [I] Control (placebo
      injection; no exercise), [II] Anakinra (100 mg subcutaneous injection of human recombinant
      interleukin-1 receptor antagonist), [III] Exercise (1 h cycle ergometry at 75% VO2max), [IV]
      Anakinra + Exercise. Pancreatic beta-cell function (plasma insulin responses) will be
      measured before and after each intervention using a hyperglycemic clamp (5.4 mM above basal
      glucose) combined with GLP-1 infusion (0.5 pmol/kg/min) and arginine injection (5 g bolus).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI relocated to a different country and coI moved to a different lab.
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 30, 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-cell function</measure>
    <time_frame>1 day after intervention</time_frame>
    <description>A hyperglycemic clamp will be performed combined with glucagon-like peptide(GLP)-1 infusion and arginine injection. The primary outcome is the insulin secretory response to glucose, GLP-1, and arginine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose disposition</measure>
    <time_frame>1 day after intervention</time_frame>
    <description>The glucose disposal rate during hyperglycemic clamp</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control (CON)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra (AN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise (EX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra + Exercise (ANEX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (AN)</intervention_name>
    <arm_group_label>Anakinra (AN)</arm_group_label>
    <arm_group_label>Anakinra + Exercise (ANEX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise (EX)</intervention_name>
    <arm_group_label>Exercise (EX)</arm_group_label>
    <arm_group_label>Anakinra + Exercise (ANEX)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control (CON)</intervention_name>
    <arm_group_label>Control (CON)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with HbA1c &gt;7%

        Exclusion Criteria:

          -  HbA1c &gt;7%

          -  Age &lt;30 or &gt;80 y

          -  BMI &lt;25 or &gt;40 kg/m2

          -  Pregnancy

          -  Evidence of chronic haematological/renal/hepatic/pulmonary/heart disease

          -  &gt;2kg weight change in prior 6 months

          -  Alcohol consumption (men: &gt;14 drinks/week; women: &gt;7 drinks/week)

          -  Smoking

          -  Physical activity of &gt;150 min/week

          -  Contraindication to exercise

          -  Contraindication to use of anakinra
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas P Solomon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet &amp; University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Solomon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>IL-1RA</keyword>
  <keyword>Beta-cell function</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

